Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colerectal carcinoma

Cancer Immunology Immunotherapy

Volumn 48, Issue 8, 1999, Pages 463-470

  Hjelm Skog, A L ^a,b   Ragnhammar, P ^b   Fagerberg, J ^a,b   Frodin J E ^b   Goldinger, M ^c   Koldestam, H ^c   Liljefors, M ^b   Nilsson, B ^b   Shetye, J ^a   Wersall P ^b   Mellstedt, H ^a,b  

^a Cancer Centre Karolinska   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Colorectal carcinoma; GM CSF IL 2; Monoclonal antibodies

Indexed keywords

EDRECOLOMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; REMISSION; SURVIVAL TIME; TUMOR IMMUNITY;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; CALCIUM; COLORECTAL NEOPLASMS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MICE; MIDDLE AGED; SERUM ALBUMIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032746922     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050623     Document Type: Article

References (33)

1. American Academy of Allergy and Immunology (1983) Position statement: skin testing and radioallergosorbent testing (RAST) for diagnosis of specific allergens responsible for IgE-mediated diseases. Allergy Clin Immunol 72:515
2. Bajorin DF, Chapman PB, Wong G, Coit DG, Kunicka J, Dimaggio J, Cordon-Cardo C, Urmacher C, Dantes L, Templeton MA, Liu J, Oettgen HF, Houghton AN (1990) Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 50:7490
3. Böyum A (1968) A one stage procedure for isolation of granulocytes and lymphocytes from human blood. Scand J Clin Lab Invest 21:51
4. Chachoua A, Oratz R, Liebes L, Alter RS, Felice A, Peace D, Vilcek J, Blum RH (1994) Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. J Immunother 16:132
5. Fagerberg J, Hjelm A-L, Ragnhammar P, Frödin J-E, Wigzell H, Mellstedt H (1995) Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idio-type-reactive T lymphocytes. Cancer Res 55:1824
6. Fagerberg J, Ragnhammar P, Liljefors M, Hjelm AL, Mellstedt H, Frödin JE (1996) Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 42:81
7. Farace F, Angevin E, Dietrich P-Y, Leboullaire C, Vanderplancke J, Escdier B, Triebel F (1995) Low-dose IL-2 treatment: activation of discrete T- and NK-cell subpopulations in vivo. Int J Cancer 62:523
8. Frödin J-E, Harmenberg U, Biberfeld P, Christensson B, Lefvert A-K, Rieger Å, Shetye J, Wahren B, Mellstedt H (1988) Clinical effects of monoclonal antibodies (mAb17-1A) in patients with metastatic colorectal carcinomas. Hybridoma 7:309
9. 1). An important antitumoral effector function? Hybridoma 10:421
10. Herlyn DM, Koprowski H (1981) Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity. Int J Cancer 27:769
11. Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T, Kishimoto S (1988) Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res 48:1173
12. Masucci G, Wersäll P, Ragnhammar P, Mellstedt H (1989) Granulocyte/monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 29:288
13. Masucci G, Wersäll P, Nielsen J, Kierulff Nielsen H, Wigzell H, Mellstedt H (1989) Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using mAb17-1A: a combination of potential usefulness in tumor therapy. Hybridoma 8:507
14. Masucci G, Ragnhammar P, Wersäll P, Mellstedt H (1990) Granulocyte/monocyte-colony-stimulating factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb17-1A). Cancer Immunol Immunother 31:231
15. Morgan AC Jr, Sullivan W, Graves S, Woodhouse CS (1989) Murine monoclonal IgG3 to human colorectal tumor associated antigens. Enhancement of antibody-dependent cell-mediated cytotoxicity by interleukin 2. Cancer Res 49:2773
16. Munn DH, Cheung N-K (1987) Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 47:6600
17. Ragnhammar P, Masucci G, Frödin JE, Hjelm A-L, Mellstedt H (1992) Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb17-1A and granulocyte/macrophage-colony-stimulated factor. Cancer Immunol Immunother 35:158
18. Ragnhammar P, Fagerberg J, Frödin J-E, Hjelm A-L, Lindemalm C, Magnusson I, Masucci G, Mellstedt H (1993) Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - long-lasting, complete remissions can be induced. Int J Cancer 53:751
19. Ragnhammar P, Friesen H-J, Frödin J-E, Lefvert A-K, Hassan M, Österborg A, Mellstedt H (1994) Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 84:4078
20. Ragnhammar P, Blomgren H, Edler D, Lundell G, Magnusson I, Sonnenfeld T (1995) Different dose regimens of 5-fluorouracil and IFN-alpha in patients with metastatic colorectal carcinoma. Eur J Cancer 31:315
21. Ragnhammar P, Fagerberg J, Frödin JE, Wersäll P, Hansson L-O, Mellstedt H (1995) Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies. Cancer Immunol Immunother 40:367
22. Ragnhammar P, Frödin J-E, Hjelm A-L, Fagerberg J, Wersäll P, Lindemalm C, Nilsson B, Fox K, Magnusson I, Ewerth S, Thor K, Secher E, Mellstedt H (1995) Different dose regimens of the mouse monoclonal antibody 17-1A for therapy of patients with metastatic colorectal carcinoma. Int J Oncol 7:1049
23. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J and the German Cancer Aid 17-1A Study Group (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1177
24. Ruscetti F, Palladino M (1991) Transforming growth factor-ß and the immune system. Prog in Growth Factor Res 3:159
25. Santoli D, Clark SC, Kreider BL, Maslin PA, Rovera G (1988) Amplification of IL-2 driven T cell proliferation by recombinant human IL-3 and GM-CSF. J Immunol 141:519
26. Schiller JH, Hank JA, Khorsand M, Storer B, Borchert A, Huseby-Moore K, Burns D, Wesly O, Albertini MR, Wilding G, Sondel PM (1996) Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study. Clin Cancer Res 2:319
27. Seemayer TA, Schûrch W, Lagace R (1981) Myofibroblasts in human pathology. Hum Pathol 12:491
28. Shetye J, Christensson B, Rubio CA, Rodensjö M, Biberfeld P, Mellstedt H (1989) The tumor-associated antigens BR55-2, GA73-3 and GICA19-9 in normal and corresponding neoplastic human tissues. Anticancer Res 9:395
29. Shetye J, Ragnhammar P, Liljefors M, Christensson B, Frödin J-E, Biberfeldt P, Mellstedt H (1998) Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 8:1921
30. Shiloni E, Eisenthal A, Sachs D, Rosenberg S (1987) Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol 138:1992
31. SPSS (1988) Base 8.0 Application guide. SPCC Inc, Chicago. p 105
32. 2a antibodies to tumors destroy human cancer cells. Science 221:865
33. Wadhwa M, Bird C, Fagerberg J, Gaines-Das R, Ragnhammar P, Mellstedt H, Thorpe R (1996) Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin Exp Immunol 104:351